Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
OMIM | RCV000005370 | SCV000025550 | risk factor | Hypertension, salt-sensitive essential, susceptibility to | 2004-12-01 | no assertion criteria provided | literature only | |
Pharmacy Department, |
RCV002292440 | SCV002500936 | drug response | Tacrolimus response | 2022-04-15 | no assertion criteria provided | research | The risk of immunological complications is generally highest during the early period after kidney transplantation. Adequate immunosuppression is crucial during this critical period since lower tacrolimus exposure at approximately one week post-kidney transplantation has been associated with subsequently higher rates of acute rejection [Undre 1999, Borobia 2009, O’Seaghdha 2009, Richards 2014]. The very low dosage of 60 mg/day diltiazem affects tacrolimus exposure in CYP3A5 expressers and may reduce tacrolimus dosage requirement in CYP3A5 expressers to achieve the same exposure of the drug in nonexpressers during the first week after kidney transplantation. |
Department of Neurology lab, |
RCV002227926 | SCV002503584 | association | refractory myasthenia gravis | 2022-03-23 | no assertion criteria provided | clinical testing | Genetic polymorphisms of CYP3A5 influence the blood trough concentration and efficacy of tacrolimus for myasthenia gravis patients. CYP3A5 rs776746 were predictive factors for refractory myasthenia gravis. |
Pharmacy Practice Department, |
RCV002292440 | SCV002506611 | drug response | Tacrolimus response | 2021-12-31 | no assertion criteria provided | research | Fluctuation of tacrolimus exposure in an individual transplant recipient has been recognized as a tool for identifying patients at risk of poor outcomes (Shuker 2016, Gonzales 2020). No evidence of impact of the CYP3A5 genetic polymorphisms on tacrolimus intra-patient variability of dose-adjusted trough concentrations during 6 to 12 months after kidney transplantation was determined. However, significant influence of the polymorphisms on tacrolimus exposure was found when comparing CYP3A5 expressers with nonexpressers at months 6, 9, and 12 after transplantation, with large effect. |